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Since coronary artery disease (CAD) is the primary cause of death in women after the age of 60 years, measures to reduce the risk for CAD should be taken by women as they are in men. In addition to the established recommendations to stop smoking, eat a balanced diet, lower cholesterol levels, treat hypertension and diabetes mellitus and keep physically fit, there is now a growing interest in learning and understanding the cardioprotective properties of hormone replacement therapy (HRT)1. A large body of evidence shows that oestrogen use after the menopause reduces the incidence of CAD up to 50%, and the use of progestin as co-medication does not seem to attenuate this effect2. Moreover, oestrogens may act in a gender-specific way on vessel walls, enhancing the synthesis and release of nitric oxide (NO) and other vasodilators and inhibiting the synthesis and release of vasoconstrictor agents, thus leading to vasorelaxation and an increase in blood flow and tissue perfusion3-5. To understand the mechanisms by which oestrogen protects the cardiovascular system, one must also look at the effect of oestrogen on various cardiovascular risk factors. Indeed, many studies show that oestrogen favourably alters the cardiovascular risk factor profile through its metabolic effects on lipids and lipoproteins, lipoprotein (a), serum homocysteine level, haemostasis and insulin-carbohydrate interactions5-7. All these add up to create a better risk profile for hormone users. The question whether HRT affects blood pressure remains controversial8. The PEPI trial did not demonstrate such an effect9, whilst some smaller scale studies did10'11. In addition to primary prevention, data have also started to accumulate on secondary prevention of CAD by HRT. In animals oestrogen was shown to retard the development of atherosclerosis and restore endothelial function in diseased vessels. Women with documented CAD who use hormones were shown to have a better prognosis than non-users7. On the basis of these data, it is now recommended that HRT should be taken by women with known CAD or those at Discussing HRT in the aged is more difficult. First, HRT is rarely prescribed in this age group; and, second, the level of adherence to HRT is poor, and few women continue to take it beyond the age of 65 or 70 years. In a community study in North Carolina only 6% of women above 65 years were taking hormones, although 19% reported past use15. In another cohort followed from age 58 to age 81 years, only 7% of hormone users were still taking oestrogen by the end of follow-up16. Compliance was also found to be poor in the multicentre Study of Osteoporotic Fractures: current use of hormones declined sharply with age from 17% at age 65 years to 4% at age >85 years17. The main reasons for stopping the medications were a feeling that it was not needed (31%), undesirable side effects (16%), and a second opinion from another physician (13%). As a result we are short of data on the cardioprotective effects of HRT in the old, with regard to both primary and secondary prevention18. (Table 1) The largest published series on primary prevention was the Nurses' Health Study in the United States, in which 60 000 postmenopausal women participated2. The relative risk for major coronary event over a 16-year follow-up was 0.6 for oestrogen users and 0.4 for combined oestrogen-progestogen users compared with never users. The relative risk for stroke was not changed by HRT. The mean age for users was 58 years, and the oldest woman at the end of follow-up was only 71 years old. The beneficial effects of HRT for women older than 60 years were similar to those in younger women. Another study from the United States described the results of hormone use for a mean duration of 17 years (minimum 5 years) in women with a mean age of 78 years at study termination19. The relative risk for death from CAD in ever users compared with never users was 0.4. Interestingly, a retrospective case-control study from the same health care provider looked at women admitted to hospital for acute MI20 and found no decrease in the odds The median age at the beginning of the study was 73 years, and mean follow-up was 7.5 years. All-cause mortality was 20% lower in oestrogen ever users than in never users. The relative risk for death as a result of acute MI in ever users was 0.6 and a treatment period of more than 15 years was associated with a relative risk of 0.5. Very similar results were obtained in the Lipid Research Clinics Program23, where oestrogen users, including a group aged 70-79 years, had one-half the cardiovascular mortality of non-users during 8.5 years of follow-up. Unfortunately, other largescale studies which demonstrated a cardioprotective effect did not analyse specifically the older age groups. Of the 23 000 who were included in a Swedish cohort from Uppsala, about 10% were older than 65 years24 but data were presented only for women less than 60 years old compared with those age 60 and over. In the Iowa Women's Health Study25, which recruited more than 40 000 women between 55 and 69 years old, no data specific to the older age groups were presented. (Note that the data from the US mainly concern women taking conjugated equine oestrogens, while the data from Europe are mainly associated with oestradiol use.) We still await a well-designed, prospective, double-blind, placebo controlled long-term study on primary prevention of CAD. The Women's Health Initiative, sponsored by the National Institutes of Health, planned to end in 2006, is expected to collect valuable information on this issue: 27500 women will be studied, the follow-up will last for 9 years, twothirds of the cohort will be 60-80 years old, and the primary end-points are morbidity and mortality from CAD. Data are also lacking with regard to the effect of HRT on the risk profile for CAD in older women. The Cardiovascular Health Study examined 3000 women above 65 years, looking at risk factors for CAD and stroke in present, past and never users of oestrogen26. The results resembled those found in younger women-better lipid profile, lower fibrinogen, factor 7 and insulin, decreased left ventricular mass, thinner carotid artery walls, fewer carotid stenoses. Stratification by age showed the same effects for women aged 65-74 years and those older than 75 years.
PRIMARY PREVENTION OF CAD BY HRT
Secondary prevention of CAD by HRT A far more important issue is the effects of hormones in already established CAD. In-vitro and in-vivo studies showed that oestrogen is capable of restoring the arterial wall and endothelial function in atherosclerotic vessels through its effect on the nitric oxide pathway, prostacyclins, endothelin and other mediators27. Moreover, oestrogens retard the development of arterial atherosclerotic lesions. Small-scale angiographic studies showed that, at the time of the procedure, HRT use was associated with a lesser degree of coronary artery stenosis28 29. Several prospective studies demonstrated a better prognosis for hormone users with established CAD. Newton et a]. examined a cohort (mean age 66 years) followed over at least 3 years after surviving an acute MI30. The odds ratios associated with current hormone use were 0.64 for reinfarction and 0.5 for allcause mortality. A 1 0-year follow-up study by Sullivan et a]. on women with angiographically proven coronary atherosclerosis at baseline showed better survival for hormone ever users, especially in those with more severe coronary disease31. Women were almost 70 years old at study termination. Odds ratio for death was 0.16. The same investigators also looked at survival after coronary artery bypass grafting32. Again, a beneficial effect of oestrogen was documented, but the women were only 60 years old at the end of follow-up. Another study, by O'Keefe et al. 33 , examined the consequences of coronary angioplasty in wvomen with a mean age of 62 at baseline. As expected, cardiovascular events (cardiovascular mortality or reinfarction) occurred less frequently in women using hormones over 7 years of follow-up (relative risk 0.38). As already mentioned in connection with primary prevention, definitive answers on secondary prevention by HRT might be available when data emerge from suitably designed double-blind, placebo-controlled studies. One such ongoing investigation is the Heart and Estrogen/Progestin Replacement Study (HERS), which started in the United States in 1993. The investigators enrolled 2500 postmenopausal women younger than 80 years of age who had documented CAD. Women were randomly allocated to hormone or placebo treatment, follow-up is to be 5 years and the first results will be reported shortly. Meanwhile, it is highly recommended that women who already have CAD or are at higher than usual risk take hormone replacement12 13. Old age should not be considered an obstacle: HRT may be started at any age, and should be taken continuously for life, if possible. Existing data on older women who use hormones are encouraging. However, since the benefit for healthv early postmenopausal women might be relatively small, w,,-e suggest that symptom-free women without risk factors for CAD or osteoporosis could start HRT not at the beginning of menopause but rather after the age of 60, to achieve maximum cardioprotective effect when CAD is most prevalent while possibly circumventing some of the risks associated with long-term HRT.
